Strassburg Ch P
Abteilung für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover.
Praxis (Bern 1994). 2005 Jan 19;94(3):73-81. doi: 10.1024/0369-8394.94.3.73.
The recent years have seen significant progress in the area of genetically determined liver diseases. For hereditary hemochromatosis, Wilson's disease and alpha-1 antitrypsin deficiency the underlying genetic defects have been described and well characterized. Although a direct relationship between genetic defect and disease manifestation exists genetic test only have a limited diagnostic usefulness which requires exact knowledge of the underlying molecular pathology. The classical C282Y and H63D mutations of the HFE gene only show a penetrance of 10-20% in hemochromatosis and are not useful for population screening. Genetic screening for ATP7B (Wilson's disease) and alpha-1 antitrypsin deficiency variants is limited by the existence of a plethora of individual mutations. Genetic tests are mainly restricted to the counseling of families in whom these diseases are present. Foremost the diagnosis of the three diseases is reached by clinical, biochemical and in some instances also histological means which are supplemented and confirmed by the use of appropriate genetic tests.
近年来,在基因决定的肝脏疾病领域取得了显著进展。对于遗传性血色素沉着症、威尔逊氏病和α-1抗胰蛋白酶缺乏症,其潜在的基因缺陷已被描述并得到充分表征。尽管基因缺陷与疾病表现之间存在直接关系,但基因检测的诊断用途有限,这需要对潜在的分子病理学有确切的了解。HFE基因的经典C282Y和H63D突变在血色素沉着症中的外显率仅为10%-20%,对人群筛查无用。ATP7B(威尔逊氏病)和α-1抗胰蛋白酶缺乏症变体的基因筛查受到大量个体突变的限制。基因检测主要限于对患有这些疾病的家庭进行咨询。这三种疾病的诊断首先通过临床、生化手段,在某些情况下还通过组织学手段实现,适当的基因检测对其进行补充和确认。